Europe Laboratory Developed Tests Market To Reach $6.5 Billion By 2030

Europe Laboratory Developed Tests Market Growth & Trends

The Europe laboratory developed tests market size is anticipated to reach USD 6.4 billion by 2030 and is projected to grow at a CAGR of 7.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing demand for personalized medication, rising prevalence of cancer, and the growing demand for IVD tests currently unavailable in the market are the major factors contributing to the market growth. The 2.3% rise in a number of cancer cases in Europe in 2022, as compared to 2020, to reach a number of around 2.74 million is a major healthcare concern.

The increasing number of deaths caused by non-communicable diseases such as ischemic heart disease, stroke, Alzheimer’s disease and other dementia highlights the need for early disease detection. Moreover, diabetes, one more type of non-communicable disease, is a global threat and has also affected Europe, with around 60 million cases across the region. Furthermore, the rising healthcare costs and common medicines not being effective in treating large numbers of patients have led to opting for the option of personalized medication.

Government-sponsored initiatives, such as the European PANCAID and PANCAIM projects, are aiding in the diagnosis and treatment of cancer. The amendments in European in-vitro medical devices regulations in 2022 have relaxed the conditions to be met by health institutions making laboratory developed tests, also known as in-house devices placing on the market and put into service. The launch of the European Partnership for Personalised Medicine (EP PerMed) in 2023 is anticipated to boost research in European precision medicine, increasing the demand for R&D and adoption of laboratory developed tests, driving the market growth in Europe.

 Request a free sample copy or view report summary: Europe Laboratory Developed Tests Market Report

Europe Laboratory Developed Tests Market Report Highlights

• Based on technology, the molecular diagnostics segment led the market with a largest revenue share of 26% in 2023, owing to its prominent applications in disease diagnosis at gene level

• Based on application, the nutritional and metabolic disease application segment is expected to grow at the fastest CAGR over the forecast period

• Based on application, the oncology segment held the market with the largest revenue share of 21% in 2023, owing to the rising incidence in the region. Factors such as sedentary lifestyle, increasing incidences of smoking, and lack of exercise are contributing to the growing prevalence of cancer and metabolic diseases

• In November 2023, F. Hoffmann-La Roche Ltd launched its next generation qPCR system LightCycler PRO. This system is expected to help testing patients for cancer, infectious diseases, and other public health challenges

Europe Laboratory Developed Tests Market Segmentation

Grand View Research has segmented the Europe laboratory developed tests market based on the technology, application, and country.

Europe Laboratory Developed Tests Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Immunoassays

• Hematology and coagulation

• Molecular diagnostics

• Microbiology

• Clinical chemistry

• Histology/Cytology

• Flow cytometry

• Mass spectroscopy

• Others

Europe Laboratory Developed Tests Application Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

  • Companion diagnostics

  • Genomics sequencing and others

• Genetic disorders/inherited diseases

• Infectious and parasitic diseases

• Immunology

• Endocrine

• Nutritional and metabolic diseases

• Cardiology

• Mental/behavioral disorder

• Pediatrics-specific testing

• Hematology/general blood testing

• Body fluid analysis

• Toxicology

• Other diseases

Europe Laboratory Developed Tests Country Outlook (Revenue, USD Million, 2018 - 2030)

• UK

• Germany

• France

• Italy

• Spain

• Denmark

• Sweden

• Norway

List of Key Players in the Europe Laboratory Developed Tests Market Include

• Abbott

• Guardant Health

• Siemens Healthineers AG

• Quest Diagnostics

• Qiagen

• Eurofins Scientific

• Illumina, Inc.

• F.Hoffmann La-Roche Ltd

• SVAR Lifesciences

• Biomérieux

• BD